Lars Hanker
Overview
Explore the profile of Lars Hanker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wimberger P, Pfisterer J, du Bois A, Hilpert F, Kerkmann M, Sehouli J, et al.
Eur J Surg Oncol
. 2025 Mar;
51(6):109696.
PMID: 40048960
Objectives: The German quality assurance program (QS-Ovar) representatively documents treatment and survival for patients with the initial diagnosis of primary ovarian cancer in the third quarters of 2004, 2008, 2012,...
2.
Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, et al.
Int J Gynecol Cancer
. 2025 Jan;
35(1):100001.
PMID: 39878257
Objective: The Laparoscopic Approach to Cervical Cancer trial demonstrated that minimally invasive radical hysterectomy was associated with worse disease-free survival and overall survival among women with early-stage cervical cancer. It...
3.
Kwon J, McTaggart-Cowan H, Ferguson S, Samouelian V, Lambaudie E, Guyon F, et al.
J Gynecol Oncol
. 2024 Oct;
35(6):e117.
PMID: 39453395
Objective: SHAPE (Simple Hysterectomy And PElvic node assessment) was an international phase III trial demonstrating that simple hysterectomy was non-inferior to radical hysterectomy for pelvic recurrence risk, but superior for...
4.
Krell J, Shaw D, McGrane J, Hartkopf A, Herrero A, Yeoh C, et al.
Future Oncol
. 2024 Oct;
20(40):3409-3419.
PMID: 39445504
The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced...
5.
Ramachandran D, Tyrer J, Kommoss S, DeFazio A, Riggan M, Webb P, et al.
NPJ Genom Med
. 2024 Mar;
9(1):19.
PMID: 38443389
Survival from ovarian cancer depends on the resection status after primary surgery. We performed genome-wide association analyses for resection status of 7705 ovarian cancer patients, including 4954 with high-grade serous...
6.
Banys-Paluchowski M, Brus L, Krawczyk N, Kopperschmidt S, Gasparri M, Bundgen N, et al.
Arch Gynecol Obstet
. 2023 Aug;
309(1):269-280.
PMID: 37584773
Purpose: The use of autologous tissues is considered gold standard for patients undergoing breast reconstruction and is the preferred method in the post-radiation setting. Although the latissimus dorsi flap (LDF)...
7.
Heublein S, Baum J, Jaeger A, Grimm-Glang D, Olthoff J, Braicu E, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046699
Background: Surgery is the backbone of early-stage ovarian cancer (OC) management. However, in practice, there is disagreement about the extent of surgical staging and whether additional adjuvant treatment should be...
8.
Wimberger P, Pfisterer J, du Bois A, Hilpert F, Kerkmann M, Sehouli J, et al.
Int J Gynecol Cancer
. 2023 Mar;
33(7):1083-1089.
PMID: 37001891
Objective: The quality assurance program for ovarian cancer (QS-OVAR) evaluates the implementation of treatment standards and impact on survival for International Federation of Gynecology and Obstetrics (FIGO) stage I ovarian...
9.
Roser E, Harter P, Zocholl D, Denschlag D, Chekerov R, Wimberger P, et al.
Int J Gynecol Cancer
. 2023 Jan;
33(2):223-230.
PMID: 36631151
Objective: Gynecological sarcomas account for 3% of all gynecological malignancies and are associated with a poor prognosis. Due to the rarity and heterogeneity of gynecological sarcomas there is still no...
10.
Pervan M, Gembicki M, Princk H, Rody A, Hanker L, Hemptenmacher F, et al.
Arch Gynecol Obstet
. 2022 Dec;
308(4):1379-1380.
PMID: 36539622
After performing laparoscopic unilateral adnexectomy in a 53-year-old woman for a rapidly grown unilateral adnexal mass, pathologists reported a primary ovarian leiomyoma with no genuine ovarian tissue. This rare diagnosis...